[go: up one dir, main page]

FI946066A0 - Nya sekvenser av genotyperna av hepatit-C-virus och användning av dessa som terapeutiska och diagnostiska medel - Google Patents

Nya sekvenser av genotyperna av hepatit-C-virus och användning av dessa som terapeutiska och diagnostiska medel

Info

Publication number
FI946066A0
FI946066A0 FI946066A FI946066A FI946066A0 FI 946066 A0 FI946066 A0 FI 946066A0 FI 946066 A FI946066 A FI 946066A FI 946066 A FI946066 A FI 946066A FI 946066 A0 FI946066 A0 FI 946066A0
Authority
FI
Finland
Prior art keywords
hepatitis
therapeutic
diagnostic agents
new sequences
present
Prior art date
Application number
FI946066A
Other languages
English (en)
Finnish (fi)
Other versions
FI946066A (sv
Inventor
Geert Maertens
Lieven Stuyver
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of FI946066A0 publication Critical patent/FI946066A0/sv
Publication of FI946066A publication Critical patent/FI946066A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI946066A 1993-04-27 1994-12-23 Nya sekvenser av genotyperna av hepatit-C-virus och användning av dessa som terapeutiska och diagnostiska medel FI946066A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93401099 1993-04-27
EP93402019 1993-08-05
PCT/EP1994/001323 WO1994025601A2 (en) 1993-04-27 1994-04-27 New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents

Publications (2)

Publication Number Publication Date
FI946066A0 true FI946066A0 (sv) 1994-12-23
FI946066A FI946066A (sv) 1994-12-23

Family

ID=26134679

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946066A FI946066A (sv) 1993-04-27 1994-12-23 Nya sekvenser av genotyperna av hepatit-C-virus och användning av dessa som terapeutiska och diagnostiska medel

Country Status (15)

Country Link
US (3) US7157226B1 (sv)
EP (4) EP1004670B1 (sv)
JP (5) JPH07508423A (sv)
CN (1) CN1108030A (sv)
AT (4) ATE552340T1 (sv)
AU (1) AU688323B2 (sv)
BR (1) BR9405334A (sv)
CA (2) CA2139100C (sv)
DE (1) DE69435023T2 (sv)
ES (1) ES2294779T3 (sv)
FI (1) FI946066A (sv)
NO (1) NO944967L (sv)
NZ (1) NZ266148A (sv)
SG (1) SG50563A1 (sv)
WO (1) WO1994025601A2 (sv)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3688290B2 (ja) * 1991-11-21 2005-08-24 コモン サーヴィシス エージェンシー Ｃ型肝炎ウイルス検査
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6380376B1 (en) * 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US7258977B1 (en) * 1992-11-27 2007-08-21 Innogenetics N.V. Process for typing of HCV isolates
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
EP1004670B1 (en) 1993-04-27 2012-04-11 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
DE69434116T2 (de) 1993-05-05 2005-10-27 Common Services Agency Hepatitis-c virus typ 4,5 und 6
US5882852A (en) * 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
US7070790B1 (en) 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5514539A (en) 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
EP0804584B2 (en) 1994-10-21 2008-07-09 Innogenetics N.V. Sequences of hepatitis c virus genotype 7 and their use as prophylactic, therapeutic and diagnostic agents
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
WO1998012332A1 (en) * 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
BRPI9909678B8 (pt) 1998-04-17 2021-05-25 Fujirebio Europe N V aperfeiçoados ensaios de imunodiagnóstico usando agentes redutores
AU4497999A (en) * 1998-04-28 1999-11-16 Ingrid-Corina Bergter Radioimmunopharmaca for treating hepatitis c
WO1999063941A2 (en) * 1998-06-09 1999-12-16 Branch Andrea D Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
WO2005004910A2 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
JP4837229B2 (ja) * 2000-06-15 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗ｈｃｖ抗体についてのイムノアッセイ
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU9215101A (en) * 2000-08-17 2002-02-25 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7196183B2 (en) * 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
MD2149G2 (ro) * 2001-11-23 2003-10-31 Институт Генетики И Физиологии Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
ATE556084T1 (de) * 2002-03-11 2012-05-15 Lab 21 Ltd Verfahren und zusammensetzungen zur identifizierung und charakterisierung von hepatitis c
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
ES2596753T3 (es) 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
CA2552949C (en) * 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
US20060162667A1 (en) * 2005-01-26 2006-07-27 Papadoyianis Ernest D Aquatic habitat and ecological tank
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US8067208B2 (en) 2005-06-30 2011-11-29 Roche Molecular Systems, Inc. Probes and methods for hepatitis C virus typing using multidimensional probe analysis
MD3300G2 (ro) * 2006-09-28 2007-11-30 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Primer oligonucleotidic pentru depistarea ARN-ului virusului hepatitei C
WO2008046922A2 (en) * 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for anaysis of sequence variations within the hcv ns5b genomic region
WO2008046923A2 (en) 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
US20090325145A1 (en) 2006-10-20 2009-12-31 Erwin Sablon Methodology for analysis of sequence variations within the hcv ns5b genomic region
WO2009022939A1 (fr) * 2007-08-09 2009-02-19 Uchrezhdenie Rossiiskoi Akademii Nauk Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Ran (Imb Ran) Procédé d'identification du génotype et du sous-type du virus de l'hépatite c sur une biopuce
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009059021A2 (en) * 2007-10-30 2009-05-07 Intermune, Inc. Hcv genotyping and phenotyping
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
EP2414839B1 (fr) * 2009-03-30 2014-06-25 Biomérieux Support solide de détection du vhc
WO2013150450A1 (en) * 2012-04-02 2013-10-10 Universidade Do Porto Hcv homolog fragments, cell-lines and applications thereof
DK3274478T3 (da) * 2015-03-27 2020-11-23 Ortho Clinical Diagnostics K K Hcv-ns4a/modificerede ns3-polypeptider og anvendelser deraf
JP6999645B2 (ja) * 2016-08-02 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 核酸の増幅及び検出／定量の効率を改良するためのヘルパーオリゴヌクレオチド

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
HU220204B (hu) * 1987-11-18 2001-11-28 Chiron Corp. HCV polipeptidek és HCV polinukleotidok, ilyen polinukleotidokat tartalmazó vektorok és ezekkel transzformált gazdasejtek, valamint HCV fertőzés kimutatására szolgáló diagnosztikumok és immunvizsgálati készlet
GB2236819B (en) * 1989-09-14 1993-07-14 Gen Motors France Dual master cylinder
WO1991004262A1 (en) 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AU642942B2 (en) 1989-12-18 1993-11-04 Wellcome Foundation Limited, The Viral agent
EP0435229A1 (en) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNA of non-A, non-B hepatitis virus gene, its clone and use thereof
WO1991014779A1 (en) * 1990-03-28 1991-10-03 Mitsui Toatsu Chemicals, Incorporated Diagnostic for hepatitis virus
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
FI913068A (fi) 1990-06-25 1991-12-26 Univ Osaka Res Found Non-a-, non-b-hepatitisviruspartiklar.
DK0754704T3 (da) 1990-12-14 2000-04-03 Innogenetics Nv Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
PL169880B1 (pl) 1991-05-08 1996-09-30 Chiron Corp Sposób wytwarzania produktu hybrydyzacji z kwasem nukleinowym wirusa zapalenia watroby C PL PL PL
JP3516681B2 (ja) 1991-06-24 2004-04-05 カイロン コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）ポリペプチド
EP0532167A3 (en) 1991-08-09 1993-03-31 Immuno Japan Inc. Non-a, non-b hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
AU2513592A (en) * 1991-08-21 1993-03-16 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
ATE228564T1 (de) * 1991-09-13 2002-12-15 Chiron Corp Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
JP3688290B2 (ja) * 1991-11-21 2005-08-24 コモン サーヴィシス エージェンシー Ｃ型肝炎ウイルス検査
ATE507312T1 (de) * 1992-11-27 2011-05-15 Innogenetics Nv Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
EP1004670B1 (en) 1993-04-27 2012-04-11 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
KR100330278B1 (ko) 1993-05-10 2002-08-19 카이론 코포레이션 간염c바이러스의타이핑방법및사용시약
JPH06319563A (ja) 1993-05-13 1994-11-22 Imuno Japan:Kk Ｃ型肝炎ウイルス遺伝子、オリゴヌクレオチド、並びにｃ型 肝炎ウイルス遺伝子型判定方法
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5882852A (en) * 1993-06-29 1999-03-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hepatitic C virus (HCV) core gene nucleotide sequences and related methods of detecting major and minor genotypes of HCV isolates
JP2687852B2 (ja) * 1993-10-13 1997-12-08 日本電気株式会社 半導体メモリ装置

Also Published As

Publication number Publication date
WO1994025601A2 (en) 1994-11-10
BR9405334A (pt) 1999-05-25
EP0651807B1 (en) 2007-09-12
SG50563A1 (en) 1998-07-20
CN1108030A (zh) 1995-09-06
EP0984068B1 (en) 2012-03-28
EP0651807A1 (en) 1995-05-10
JP2002233389A (ja) 2002-08-20
ES2294779T3 (es) 2008-04-01
DE69435023D1 (de) 2007-10-25
EP0984067A3 (en) 2000-09-27
ATE373093T1 (de) 2007-09-15
AU6722294A (en) 1994-11-21
NO944967D0 (no) 1994-12-21
EP0984068A2 (en) 2000-03-08
WO1994025601A3 (en) 1995-03-02
AU688323B2 (en) 1998-03-12
EP0984067A2 (en) 2000-03-08
CA2139100C (en) 2009-06-23
ATE552340T1 (de) 2012-04-15
CA2139100A1 (en) 1994-11-10
JPH07508423A (ja) 1995-09-21
ATE553201T1 (de) 2012-04-15
EP1004670A3 (en) 2000-09-20
JP2004041207A (ja) 2004-02-12
JP2004041206A (ja) 2004-02-12
ATE551423T1 (de) 2012-04-15
US7157226B1 (en) 2007-01-02
EP1004670A2 (en) 2000-05-31
EP0984068A3 (en) 2000-09-20
EP0984067B1 (en) 2012-04-04
US20030032005A1 (en) 2003-02-13
CA2662090A1 (en) 1994-11-10
US20030008274A1 (en) 2003-01-09
EP1004670B1 (en) 2012-04-11
JP2002233388A (ja) 2002-08-20
US6762024B2 (en) 2004-07-13
NZ266148A (en) 1997-06-24
FI946066A (sv) 1994-12-23
US7195765B2 (en) 2007-03-27
NO944967L (no) 1994-12-21
DE69435023T2 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
FI946066A0 (sv) Nya sekvenser av genotyperna av hepatit-C-virus och användning av dessa som terapeutiska och diagnostiska medel
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
CA2108466A1 (en) Hcv genomic sequences for diagnostics and therapeutics
RU93058449A (ru) Hcv геномные последовательности для диагностических и терапевтических целей
RU96119350A (ru) Способ репродукции in vitro протеолитической активности ns3 протеазы вируса гепатита c(нсу)
SE9004010D0 (sv) Viralt medel
DK0770679T4 (da) HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
ATE118352T1 (de) Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits.
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
ES2175462T3 (es) Composiciones cristalizables que comprenden un complejo del dominio de proteasa ns3 del virus de la hepatitis c/ns4a, y cristales asi obtenidos.
DE69125066D1 (de) cDNS-Sequenz und Detektion des Hepatitis C-Virus
WO1992011370A3 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
Yoshioka et al. Deficiency of antibody response to hypervariable region of hepatitis C virus in patients with chronic hepatitis C
IT1270941B (it) Peptidi di hcv e loro usi.